half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
=== July === 2 July Two new satellite galaxies of the Milky Way are discovered – Sextans II and Virgo III. The fifth busy beaver is proven. 5 July – The first mouse model with a complete, functional human immune system is demonstrated. 9 July – The first local extinction due to sea level rise in the United States is reported: that of the Key Largo tree cactus (Pilosocereus millspaughii) in Florida. 11 July Using the Hubble Space Telescope, scientists resolve the 3D velocity dispersion profile of a dwarf galaxy for the first time, helping to uncover its dark matter distribution. Researchers report to have developed a cell-free system that self-regenerates using carbon dioxide (CO2). They combined an artificial metabolic network that performs CO2 fixation with cell-free protein synthesis using recombinant elements. According to the study this demonstrates how metabolic and genetic networks can be integrated and simultaneously operated outside of the cellular context towards self-maintenance of biological networks, a hallmark of life. 15 July Scientists announce the discovery of a lunar cave, approximately 250 miles (400 km) from Apollo 11's landing site. China announces a plan to visit the asteroid 2015 XF261 in 2029. Similar to NASA's Double Asteroid Redirection Test (DART), a probe will impact the body at a speed of 10 kilometres per second, and the resulting changes to its orbit will be studied. This will occur when the asteroid is within seven million kilometres of Earth.
Iron-deficiency anemia is anemia caused by a lack of iron. Anemia is defined as a decrease in the number of red blood cells or the amount of hemoglobin in the blood. When onset is slow, symptoms are often vague, such as feeling tired, weak, short of breath, or having decreased ability to exercise. Anemia that comes on quickly often has more severe symptoms, including confusion, feeling like one is going to pass out or increased thirst. Anemia is typically significant before a person becomes noticeably pale. Children with iron deficiency anemia may have problems with growth and development. There may be additional symptoms depending on the underlying cause. Iron-deficiency anemia is caused by blood loss, insufficient dietary intake, or poor absorption of iron from food. Sources of blood loss can include heavy periods, childbirth, uterine fibroids, stomach ulcers, colon cancer, and urinary tract bleeding. Poor absorption of iron from food may occur as a result of an intestinal disorder such as inflammatory bowel disease or celiac disease, or surgery such as a gastric bypass. In the developing world, parasitic worms, malaria, and HIV/AIDS increase the risk of iron deficiency anemia. Diagnosis is confirmed by blood tests. Iron deficiency anemia can be prevented by eating a diet containing sufficient amounts of iron or by iron supplementation. Foods high in iron include meat, nuts, and foods made with iron-fortified flour.
=== November === 1 November – The Commissioner for Ethical Standards in Public Life in Scotland finds SNP councillor Kairin van Sweeden in breach of the code of conduct for calling a political opponent a "New Scot" during a meeting of Aberdeen City Council in October 2023. 2 November – A 74-year-old man receives fatal injuries after being struck by a bus in Edinburgh's Cowgate. The following day, Police Scotland ask members of the public to stop sharing graphic images of the incident on social media. 3 November – Police Scotland say they have received a fresh allegation concerning a non-recent sexual assault against former First Minister Alex Salmond. 5 November – Senior consultants in Scotland have voted to accept a 10.5% pay rise that will see them earn between £10,500 and £13,500 extra each year, and which will be backdated to 1 April 2024. A waste management company is to sue the Scottish Government for £170m over the failed bottle return scheme. Bonfire Night disturbance breaks out in parts of Edinburgh, with missiles such as bricks, bottles and fireworks thrown at police. 6 November – Police Scotland say they have made 19 arrests following disturbances over Halloween and Bonfire Night. 8 November – The death certificate of Susan McGowan, a 58-year-old nurse from North Lanarkshire who died in September, has linked her death with the use of the weight loss drug tirzepatide (known under the brand name Mounjaro), which was recently approved for use on the NHS; it is reported to be the first UK death linked to the drug's use.
== Design nanoparticle self-assembly structure == Self-assembly of nanoparticles is driven by either maximization of packing density or minimization of the contact area between particles according to hard or soft nanoparticles. Examples of hard nanoparticles are: silica, fullerenes; soft nanoparticles are often organic nanoparticles, block copolymer micelles, DNA nanoparticles. The ordered self-assembly structure of nanoparticles is called superlattice.
Hoyle said the early revelations were a "supreme discourtesy to the House". 30 October – October 2024 United Kingdom budget. 31 October – 2024 Conservative Party leadership election: Voting closes for the election of the Conservative Party's next leader.
Sources: en.wikipedia.org
Compound 544678-85 is the latest pyrimidine based inhibitor, the compound is a pyrimidine-4,6-dicarboxamide that is very potent and MMP-13 selective. The compound has a specificity loop that within the S1’ pocket and its 3-methyl-4-fluoro group is proximal enough to the zinc to change the water entity. These compounds have good oral bioavailability and properties that promote them to be a good candidate for a subtype inhibitor of MMP-13 based diseases and future development. Pyrimidine dicarboxamides are highly selective MMP-13 inhibitors. In the S1’ pocket of MMP-13 is an S1’ side pocket that is unique to the matrix metalloproteiase. Pyrimidine dicarboxamides bind to this side pocket, which increases the selectivity. The role of MMP-13 is cleaving fibrillar collagen at neutral pH and higher mRNA levels of MMP-13 is detected in breast carcinoma and osteoarthritis joints. The pyrimidine dicarboxamide inhibitor example in the image does not interact with the catalytic zinc ion but rather binds to the S1’ side pocket. One pyridyl arm is situated to the entrance of the S1’ pocket while the other pyridyl arm goes through the S1’ pocket into the side pocket.
IOM Research Report TM/05/03 A normative study of levels of uranium in the urine of personnel in the British Forces Archived 26 July 2011 at the Wayback Machine by B. G. Miller, A. P. Colvin, P. A. Hutchison, H. Tait, S. Dempsey, D. Lewis, C. A. Soutar. IOM Research Report TM/05/08 Opinion on the environmental and health risks posed by depleted uranium by the Scientific Committee on Health and Environmental Risks
The theory further states that removing opiate precursors from a child's diet may allow time for these behaviors to cease, and neurological development in very young children to resume normally. As of 2021, reliable studies have not demonstrated the benefit of gluten-free diets in the treatment of autism. In the subset of people who have gluten sensitivity there is limited evidence that suggests that a gluten-free diet may improve some autistic behaviors.
His funeral in Medellín drew crowds of mourners and prompted national reflection on the violence surrounding the game. Humberto Muñoz Castro, a bodyguard employed by the alleged drug trafficker Santiago Gallón, confessed to the shooting and was sentenced to 43 years' imprisonment, of which he served eleven; investigators discounted early suggestions that gambling syndicates had ordered the killing, though the theory persisted.
Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In addition, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. Aside from the PRs and mPRs, progesterone is a potent antimineralocorticoid, or antagonist of the mineralocorticoid receptor, the biological target of the mineralocorticoid aldosterone. In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Among other neurosteroid activities, and via its active metabolites allopregnanolone and pregnanolone, progesterone is a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and in other areas of the brain. In accordance, progesterone has numerous effects throughout the body. Among other effects, progesterone produces changes in the female reproductive system, the breasts, and the brain. Progesterone has functional antiestrogenic effects due to its progestogenic activity, including in the uterus, cervix, and vagina. The effects of progesterone may influence health in both positive and negative ways. In addition to the aforementioned effects, progesterone has antigonadotropic effects due to its progestogenic activity, and can inhibit ovulation and suppress gonadal sex hormone production.
Sources: en.wikipedia.org
In 1992, the Moscow government began planning a new area in central Moscow—the Moscow International Business Center—to create a zone, the first in Russia and Eastern Europe, to combine business activity, living space, and entertainment. Situated in the Presnensky District and located at the Third Ring, the Moscow City area is undergoing intensive development. The Moscow International Business Center (MIBC) is being constructed on the Krasnopresnenskaya embankment. The project occupies up to one square kilometer (250 acres). That area is the only location in downtown Moscow able to accommodate a project of such size. Most pre-existing buildings in that area are old factories and industrial complexes. Demonstrating the MIBC's scale, the Federation Tower, completed in 2016, is the second-tallest building in Europe. The project's broader plans include a water park and other recreational facilities; business, office, entertainment, and residential buildings; a transport network; and a new site for the Moscow government. Four new metro stations in the area have been built; two of these have opened, and two others are reserved for future metro lines crossing the MIBC. Additional stations were planned. In addition, a rail shuttle service is planned to directly connect the MIBC with the Sheremetyevo International Airport. Major thoroughfares through the MIBC are the Third Ring and Kutuzovsky Prospekt. Three metro stations were initially planned for the Filyovskaya Line. The Delovoi Tsentr station opened in 2005 and was renamed Vystavochnaya in 2009.
Nefopam by mouth and cannabis are not recommended as of 2012, as the risks of use appear to be greater than the benefits. Limited evidence suggests the use of weak oral opioids, but the adverse effects may outweigh the benefits. Alternatively, physical therapy has been tested and shown as an effective aid in reducing pain in patients with RA. As most RA is detected early and treated aggressively, physical therapy plays more of a preventive and compensatory role, aiding in pain management alongside regular rheumatic therapy.
In short, information about the possible existence of an extraterrestrial civilization would come in the form of electromagnetic radiation. With regard to the fate of civilizations, Kardashev saw two concepts, from which two strategies for the search for extraterrestrial civilizations can be derived. The first, which he called "terrestrial chauvinism", is based on the principle that civilizations can only stabilize or perish at a level of development close to ours currently reached. The second, which he called the "evolutionary concept", holds that civilizations are capable of reaching higher levels of development than that of contemporary humanity. In the first case, the best search strategy using astronomical detection means (e.g., the SETI program) would be to observe the most powerful (and often the most distant) sources of radiation in space. The observer will then be able to determine if they are natural emission sources, and only then can the search focus on objects with weaker radiation. In the second case, he recommended to search for new and powerful sources of radiation, especially in the poorly known regions of the electromagnetic spectrum. These sources could be significant or periodic monochromatic signals from the galactic center, from other galaxies or from quasars and other exotic cosmic objects. Kardashev believed that the search should focus on the millimeter wavelength spectrum, close to the maximum intensity of the cosmic microwave background, rather than in the 21-centimeter band (which is the domain of investigation of the SETI program).
For light microscopy, a knife mounted in a microtome is used to cut tissue sections (typically between 5-15 micrometers thick) which are mounted on a glass microscope slide. For transmission electron microscopy (TEM), a diamond or glass knife mounted in an ultramicrotome is used to cut between 50 and 150 nanometer thick tissue sections. A limited number of manufacturers are recognized for their production of microtomes, including vibrating microtomes commonly referred to as vibratomes, primarily for research and clinical studies. Additionally, Leica Biosystems is known for its production of products related to light microscopy in the context of research and clinical studies.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.